Francesca Bruce
Senior Writer

Latest From Francesca Bruce
Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.
Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment
Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.
Canadian Court Upholds New Drug Price Comparison Basket – With Caveats
A Canadian court has dismissed an appeal brought by industry challenging new pricing rules that introduce a revised basket of reference countries as part of cost-containment measures.
Canada’s Controversial Pricing Guidelines Suspended
The implementation of new pricing guidelines that are unpopular with the pharmaceutical has been put on hold, to the relief of the pharmaceutical industry.
European Payers Target Marketing Exclusivity For Orphan Regulation Reform
European payers are calling for changes to the EU’s orphan drug rules that would transform the incentives system and avoid the market distortions enabled by the current legislation.
UK Planning To Raise Industry Repayments Under Statutory Pricing Scheme
The UK government says that payments need to rise if the stability of the statutory and voluntary drug pricing schemes is to be ensured.